vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and KFORCE INC (KFRC). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 2.4%, a 10.9% gap on every dollar of revenue. On growth, KFORCE INC posted the faster year-over-year revenue change (0.1% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-7.4M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -3.7%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
AMPH vs KFRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $330.4M |
| Net Profit | $24.4M | $7.9M |
| Gross Margin | 46.8% | 27.3% |
| Operating Margin | 19.4% | 3.6% |
| Net Margin | 13.3% | 2.4% |
| Revenue YoY | -1.8% | 0.1% |
| Net Profit YoY | -35.7% | -2.7% |
| EPS (diluted) | $0.51 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $330.4M | ||
| Q4 25 | $183.1M | $332.0M | ||
| Q3 25 | $191.8M | $332.6M | ||
| Q2 25 | $174.4M | $334.3M | ||
| Q1 25 | $170.5M | $330.0M | ||
| Q4 24 | $186.5M | $343.8M | ||
| Q3 24 | $191.2M | $353.3M | ||
| Q2 24 | $182.4M | $356.3M |
| Q1 26 | — | $7.9M | ||
| Q4 25 | $24.4M | $5.2M | ||
| Q3 25 | $17.4M | $11.1M | ||
| Q2 25 | $31.0M | $10.4M | ||
| Q1 25 | $25.3M | $8.1M | ||
| Q4 24 | $38.0M | $11.1M | ||
| Q3 24 | $40.4M | $14.2M | ||
| Q2 24 | $37.9M | $14.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | 46.8% | 27.2% | ||
| Q3 25 | 51.4% | 27.7% | ||
| Q2 25 | 49.6% | 27.1% | ||
| Q1 25 | 50.0% | 26.7% | ||
| Q4 24 | 46.5% | 27.0% | ||
| Q3 24 | 53.3% | 27.9% | ||
| Q2 24 | 52.2% | 27.8% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 19.4% | 2.6% | ||
| Q3 25 | 13.2% | 4.5% | ||
| Q2 25 | 24.2% | 4.5% | ||
| Q1 25 | 21.9% | 3.5% | ||
| Q4 24 | 24.2% | 4.5% | ||
| Q3 24 | 29.8% | 5.3% | ||
| Q2 24 | 30.3% | 5.5% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 13.3% | 1.6% | ||
| Q3 25 | 9.0% | 3.3% | ||
| Q2 25 | 17.8% | 3.1% | ||
| Q1 25 | 14.8% | 2.5% | ||
| Q4 24 | 20.4% | 3.2% | ||
| Q3 24 | 21.1% | 4.0% | ||
| Q2 24 | 20.8% | 4.0% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $0.51 | $0.29 | ||
| Q3 25 | $0.37 | $0.63 | ||
| Q2 25 | $0.64 | $0.59 | ||
| Q1 25 | $0.51 | $0.45 | ||
| Q4 24 | $0.74 | $0.60 | ||
| Q3 24 | $0.78 | $0.75 | ||
| Q2 24 | $0.73 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $1.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $117.4M |
| Total Assets | $1.6B | $384.8M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | $282.8M | $2.1M | ||
| Q3 25 | $276.2M | $1.3M | ||
| Q2 25 | $231.8M | $2.5M | ||
| Q1 25 | $236.9M | $444.0K | ||
| Q4 24 | $221.6M | $349.0K | ||
| Q3 24 | $250.5M | $127.0K | ||
| Q2 24 | $217.8M | $110.0K |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $117.4M | ||
| Q4 25 | $788.8M | $124.6M | ||
| Q3 25 | $776.7M | $132.1M | ||
| Q2 25 | $757.5M | $134.4M | ||
| Q1 25 | $751.3M | $138.0M | ||
| Q4 24 | $732.3M | $154.6M | ||
| Q3 24 | $727.7M | $167.4M | ||
| Q2 24 | $713.3M | $166.6M |
| Q1 26 | — | $384.8M | ||
| Q4 25 | $1.6B | $365.6M | ||
| Q3 25 | $1.7B | $374.2M | ||
| Q2 25 | $1.6B | $373.6M | ||
| Q1 25 | $1.6B | $368.2M | ||
| Q4 24 | $1.6B | $357.8M | ||
| Q3 24 | $1.5B | $369.9M | ||
| Q2 24 | $1.5B | $362.7M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | $-7.4M |
| FCF MarginFCF / Revenue | 13.4% | -2.2% |
| Capex IntensityCapex / Revenue | 4.5% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $19.7M | ||
| Q3 25 | $52.6M | $23.3M | ||
| Q2 25 | $35.6M | $18.4M | ||
| Q1 25 | $35.1M | $249.0K | ||
| Q4 24 | $29.0M | $21.8M | ||
| Q3 24 | $60.0M | $31.0M | ||
| Q2 24 | $69.1M | $20.9M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $24.6M | $16.7M | ||
| Q3 25 | $47.2M | $19.8M | ||
| Q2 25 | $25.0M | $14.2M | ||
| Q1 25 | $24.4M | $-3.9M | ||
| Q4 24 | $16.6M | $20.9M | ||
| Q3 24 | $46.2M | $27.5M | ||
| Q2 24 | $63.1M | $17.8M |
| Q1 26 | — | -2.2% | ||
| Q4 25 | 13.4% | 5.0% | ||
| Q3 25 | 24.6% | 6.0% | ||
| Q2 25 | 14.3% | 4.3% | ||
| Q1 25 | 14.3% | -1.2% | ||
| Q4 24 | 8.9% | 6.1% | ||
| Q3 24 | 24.1% | 7.8% | ||
| Q2 24 | 34.6% | 5.0% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 4.5% | 0.9% | ||
| Q3 25 | 2.8% | 1.1% | ||
| Q2 25 | 6.1% | 1.2% | ||
| Q1 25 | 6.3% | 1.3% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 7.2% | 1.0% | ||
| Q2 24 | 3.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 3.82× | ||
| Q3 25 | 3.03× | 2.11× | ||
| Q2 25 | 1.15× | 1.76× | ||
| Q1 25 | 1.39× | 0.03× | ||
| Q4 24 | 0.76× | 1.97× | ||
| Q3 24 | 1.48× | 2.18× | ||
| Q2 24 | 1.82× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
KFRC
Segment breakdown not available.
